The advent of therapeutic mRNAs significantly increases the possibilities of protein-based biologics beyond those that can be synthesized by recombinant technologies (eg, monoclonal antibodies, extracellular enzymes, and cytokines). In addition to their application in the areas of vaccine development, immune-oncology, and protein replacement therapies, one exciting possibility is to use therapeutic mRNAs to program undesired, diseased cells to synthesize a toxic intracellular protein, causing cells to self-destruct. For this approach to work, however, methods are needed to limit toxic protein expression to the intended cell type. Here, we show that inclusion of microRNA target sites in therapeutic mRNAs encoding apoptotic proteins, Caspase or PUMA, can prevent their expression in healthy hepatocytes while triggering apoptosis in hepatocellular carcinoma cells.
Get full access to this article
View all access options for this article.
References
1.
HajjK and WhiteheadK. (2017). Tools for translation: non-viral materials for therapeutic mRNA delivery. Nat Rev Mater, 2: [Epub ahead of print]; DOI: 10.1038/natrevmats.2017.56.
2.
SahinU, KarikóK and TureciÖ. (2014). mRNA-based therapeutics—developing a new class of drugs. Nat Rev Drug Discov, 13:759–780.
3.
KaczmarekJ, KowalskiP and AndersonD. (2017). Advances in the delivery of RNA therapeutics: from concept to clinical reality. Genom Med, 9:60.
4.
YounH and ChungJ. (2015). Modified mRNA as an alternative to plasmid DNA (pDNA) for transcript replacement and vaccination therapy. Expert Opin Biol Ther, 15:1337–1348.
5.
KotelianskiV, ZatsepinT and KotelevtsevY. (2016). Lipid nanoparticles for targeted siRNA delivery—going from bench to bedside. Int J Nanomed, 11:3077–3086.
6.
AkincA, ZumbuehlA, GoldbergM, LeshchinerES, BusiniV, HossainN, BacalladoSA, NguyenDN, FullerJ, et al. (2008). A combinatorial library of lipid-like materials for delivery of RNAi therapeutics. Nat Biotechnol, 26:561–569.
7.
LeungA, TamY, ChenS, HafezI and CullisP. (2015). Microfluidic mixing: a general method for encapsulating macromolecules in lipid nanoparticle systems. J Phys Chem B, 119:8698–8706.
8.
KauffmanKJ, DorkinJR, YangJH, HeartleinMW, DeRosaF, MirFF, FentonOS and AndersonDG. (2015). Optimization of lipid nanoparticle formulations for mrna delivery in vivo with fractional factorial and definitive screening designs. Nano Lett, 15:7300–7306.
9.
Valencia-SanchezM, LiuJ, HannonG and ParkerR. (2006). Control of translation and mRNA degradation by miRNAs and siRNAs. Genes Dev, 20:515–524.
10.
BaekD, VillénJ, ShinC, CamargoFD, GygiSP and BartelDP. (2008). The impact of microRNAs on protein output. Nature, 455:64–71.
11.
SontheimerE. (2005). Assembly and function of RNA silencing complexes. Nat Rev Mol Cell Biol, 6:127–138.
12.
HutvágnerG and ZamoreP. (2002). A microRNA in a multiple-turnover RNAi enzyme complex. Science, 297:2056–2060.
13.
LlaveC, XieZ, KasschauK and CarringtonJ. (2002). Cleavage of scarecrow-like mRNA targets directed by a class of Arabidopsis miRNA. Science, 297:2053–2056.
14.
LudwigN, LeidingerP, BeckerK, BackesC, FehlmannT, PallaschC, RheinheimerS, MederB, StählerC, MeeseE and KellerA. (2016). Distribution of miRNA expression across human tissues. Nucleic Acids Res, 44:3865–3877.
15.
LiY and KowdleyK. (2012). MicroRNAs in common human diseases. Genomics Proteom Bioinformatics, 10:246–253.
16.
LandgrafP, RusuM, SheridanR, SewerA, IovinoN, AravinA, PfefferS, RiceA, KamphorstAO, et al. (2007). A mammalian microRNA expression atlas based on small RNA library sequencing. Cell, 129:1401–1414.
17.
BrownBD, GentnerB, CantoreA, ColleoniS, AmendolaM, ZingaleA, BaccariniA, LazzariG, GalliC and NaldiniL. (2007). Endogenous microRNA can be broadly exploited to regulate transgene expression according to tissue, lineage and differentiation state. Nat Biotechnol, 25:1457–1467.
18.
BrownBD and NaldiniL. (2009). Exploiting and antagonizing microRNA regulation for therapeutic and experimental applications. Nat Rev Genet, 10:578–585.
19.
SuzukiT, SakuraiF, NakamuraS, KouyamaE, KawabataK, KondohM, YagiK and MizuguchiH. (2008). miR-122a-regulated expression of a suicide gene prevents hepatotoxicity without altering antitumor effects in suicide gene therapy. Mol Ther, 16:1719–1726.
20.
GeislerA and FechnerH. (2016). MicroRNA-regulated viral vectors for gene therapy. World J Exp Med, 6:37.
21.
AndriesO, McCaffertyS, SmedtSC, WeissR, SandersNN and Kitada.T (2015). N1-methylpseudouridine-incorporated mRNA outperforms pseudouridine-incorporated mRNA by providing enhanced protein expression and reduced immunogenicity in mammalian cell lines and mice. J Control Release, 217:337–344.
22.
CoulouarnC, FactorV, AndersenJ, DurkinM and ThorgeirssonS. (2009). Loss of miR-122 expression in liver cancer correlates with suppression of the hepatic phenotype and gain of metastatic properties. Oncogene, 28:3526–3536.
23.
RieD, AbugessaisaI, AlamT, ArnerE, ArnerP, AshoorH, ÅströmG, BabinaM, BertinN, et al. (2017). An integrated expression atlas of miRNAs and their promoters in human and mouse. Nat Biotechnol, 35:872–878.
24.
MaL, LiuJ, ShenJ, LiuL, WuJ, LiW, LuoJ, ChenQ and QianC. (2010). Expression of miR-122 mediated by adenoviral vector induces apoptosis and cell cycle arrest of cancer cells. Cancer Biol Ther, 9:554–561.
25.
XieZ, WroblewskaL, ProchazkaL, WeissR and BenensoY. (2011). Multi-input RNAi-based logic circuit for identification of specific cancer cells. Science, 333:1307–1311.
26.
AgarwalV, BellGW, NamJW and BartelDP. (2015). Predicting effective microRNA target sites in mammalian mRNAs. Elife, 4:e05005.
27.
YuJ and ZhangL. (2008). PUMA, a potent killer with or without p53. Oncogene, 27:S71–S83.
28.
NakanoK and VousdenK. (2001). PUMA, a novel proapoptotic gene, is induced by p53. Mol Cell, 7:683–694.
29.
HanahanD and WeinbergR. (2011). Hallmarks of cancer: the next generation. Cell, 144:646–674.
30.
HemannMT, ZilfouJT, ZhaoZ, BurgessDJ, HannonGJ and LoweSW. (2004). Suppression of tumorigenesis by the p53 target PUMA. Proc Natl Acad Sci U S A, 101:9333–9338.
31.
StadlerL, TomlinsonD, LeeT, KnowlesM and FerrignoK. (2014). The use of a neutral peptide aptamer scaffold to anchor BH3 peptides constitutes a viable approach to studying their function. Cell Death Dis, 5:e1037.
32.
WallerL, DeshpandeV and PyrsopoulosN. (2015). Hepatocellular carcinoma: a comprehensive review. World J Hepatol, 7:2648–2663.
33.
LeeS, LiuB, LeeS, HuangS, ShenandB and QianS. (2012). Global mapping of translation initiation sites in mammalian cells at single-nucleotide resolution. Proc Natl Acad Sci U S A, 109:E2424–E2432.
34.
GownA and WillinghamM. (2002). Improved detection of apoptotic cells in archival paraffin sections: immunohistochemistry using antibodies to cleaved caspase 3. J Mol Histol, 50:449–454.
35.
SrinivasulaSM, AhmadM, MacFarlaneM, LuoZ, HuangZ, AlnemriTF and AlnemriES. (1998). Generation of constitutively active recombinant caspases-3 and -6 by rearrangement of their subunits. J Biol Chem, 273:10107–10111.
36.
BurnettJ and RossiJ. (2012). RNA-based therapeutics: current progress and future prospects. Chem Biol, 19:60–71.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
